Gut-linked microbes tied to survival in DLBCL
The presence of certain intratumoral microbes was linked to survival outcomes in diffuse large B-cell lymphoma (DLBCL), according to findings presented at ICML
EHA 2025
2025 ASCO
Latest COMMANDS analysis shows luspatercept is transformative in MDS
In this video interview, Guillermo Garcia-Manero, MD, chief of the section of myelodysplastic syndromes at the University of Texas MD Anderson Cancer Center,
Lymphoma
‘Boom Boom Radiotherapy’ approach may boost CAR T-cell responses
The combination of so-called “Boom Boom” radiotherapy prior to treatment with lisocabtagene maraleucel (liso-cel) was found to be safe, feasible, and effective, according
News
Dr. Nieto discusses phase I results of AFM13 in lymphoma
Yago Nieto, MD, PhD, a professor at the University of Texas MD Anderson Cancer Center, discusses the results of AFM13 in a phase
Podcast
Drs. Kuykendall and Hobbs discuss the latest MPN updates, with a look ahead to ASCO® 2025
Andrew Kuykendall, MD, of Moffitt Cancer Center in Tampa, Florida hosts a podcast on the latest news in myeloproliferative neoplasms (MPNs) with guest
Aggressive B-Cell Lymphomas
Indolent B-Cell Lymphomas
News
NCCN recommends pemivibart for BCL patients at risk of severe COVID-19
Many patients with B-cell lymphomas experience reduced vaccine efficacy and may not mount an adequate immune response to vaccination, putting them at elevated
2025 ASCO
Meetings / Conferences
Early palliative care integration does not reduce MM patients’ healthcare utilization
Early integration of palliative care does not reduce the use of healthcare resources by patients with newly diagnosed multiple myeloma (MM) compared to
Multiple Myeloma
News
FDA panel votes 6-2 in favor of daratumumab for high-risk smoldering multiple myeloma
The US Food and Drug Administration (FDA)’s Oncologic Drugs Advisory Committee (ODAC) voted 6-2 that the results from the phase 3 AQUILA trial
Ambassador Program
News
Society Updates
SOHO Israel 2025 wraps up successful 2-day event with leading hematologists
The third meeting of SOHO Israel and 9th International Davidoff conference, titled State of the Art and Next Questions, was held on May
Lymphoma
News
FDA ODAC votes 8-1 glofitamab trial does not apply to US patients
A federal advisory panel voted 8-1 Tuesday that results from the global STARGLO trial, which was intended as the confirmatory trial for full